RESEARCH INTERESTS
The research in my lab focuses on the molecular pathogenesis of cerebrovascular disorders and the cell-death mechanisms underlying neurodegeneration in Alzheimer’s disease (AD), cerebral amyloid angiopathy (CAA), traumatic brain injury (TBI), and post-traumatic stress disorder (PTSD).

We analyze the effects of cellular oxidative and mitochondrial stress, apoptosis, and inflammation and explore pharmacological compounds capable of inhibiting these events. Also, we are actively searching for novel diagnostic biofluid biomarkers for AD, TBI, PTSD.

My interests have recently centered on how different amyloid aggregation species modulate molecular mechanisms and signaling pathways that trigger cell toxicity and cell stress responses in AD and CAA. In particular, we are focusing on mitochondrial dysfunction in cells comprising the neurovascular unit and in neuronal and glial cells.

We are deeply interested in the effects of amyloid variants on endothelial cell death and blood–brain barrier permeability, as well as the contribution of mitochondria, death receptors, and inflammation mediators in these events. By applying biochemical, molecular, and imaging techniques in cultured cells, animal models, and human AD or CAA brain neurovascular cells, we identified the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptors, DR4 and DR5, as targets for amyloid beta oligomers, which are responsible for the initiation of mitochondrial apoptosis in brain vascular cells.

Currently, we are studying the protective effects of carbonic anhydrase inhibitors against mitochondrial failure in amyloid-challenged cells and animal models. Our ongoing studies also explore the interactions between AD, cerebral amyloidosis, and cardiovascular risk, as well as between tau pathology and TBI and their combined effects on mitochondrial dysfunction and neurovascular cell death. Our goals are twofold: to unveil new drug development targets that can protect brain neuronal and vascular cells against neurodegeneration, cerebral hypoperfusion, and hemorrhage, and to discover new biomarkers for these diseases.

EDUCATION, TRAINING & CREDENTIALS

• Postdoctoral Fellowship, Pathology, NYU School of Medicine, New York, NY
• PhD, Pharmacology and Toxicology, University of Florence, Italy
• Research Fellowship, Pharmacology, University of Florence, Italy
• BS, Molecular Biology, University of Florence, Italy

MEMBERSHIPS

• Society for Neuroscience
• International Society to Advance Alzheimer’s Research and Treatment (ISTAART)
• American Heart Association
• Italian Scientists and Scholars in North America Foundation (ISSNAF)
• Vas-Cog Society: The international society of vascular behavioral and cognitive disorders
• Grant Reviewer for The Alzheimer’s Association, Chicago, IL
• Grant Reviewer for The Italian Ministry of Health, the Swedish Research Council, the Medical Research Council (UK), the American Institute of Biological Sciences, the Alzheimer’s Society UK
• Grant Reviewer for the National Institutes of Health (NIH)
• Grant Reviewer for US Department of Defense
• Biomarker Professional Interest Area (PIA) and Biofluid Biomarker Reference Ranges Working Group for the Alzheimer’s Association
• Vascular PIA and working group on White Matter Lesions for the Alzheimer’s Association
• US Department of Defense CDMRP PRARP Study Section

HONORS, AWARDS & APPOINTMENTS

• 2010 NYU Alzheimer’s Disease Center Pilot Grant, Center of Excellence on Brain Aging, NYU Langone Medical Center.
• 2013 Scientist Development Grant Award (2013-2017) from the American Heart Association.
• 2012 New Investigator Research Grant Award from the Alzheimer’s Association.
• 2012-2015 Research Assistant Professor, Department of Pathology, New York University School of Medicine, NY.
• 2014 Blas Frangione Foundation New Investigator Research Grant.
• 2015-2019 Director of the Biofluid Biomarkers Core of the Cohen Veteran Center, NYULMC Department of Psychiatry.
• 2015-2019 Assistant Professor, Departments of Neurology and Psychiatry; Director of the Biofluid Biomarker Core of the Cohen Veteran Center, New York University School of Medicine, NY.
• 2016 Leon Levy Fellowship in Neuroscience.
• 2020 Received the Thome Memorial Foundation Award in Alzheimer’s Disease Drug Discovery Research.
• Awarded the PA Cure Alzheimer’s disease Research Award from the PA Department of Health.
• Karen Toffler Charitable Trust Original Scholar at Temple University and Director of the Temple Scholarship Program (2020-Present). 
• 2021 Standing Member of the NOMD NIH Study Section.
• 2021-2025  Standing Member of the NOMD NIH Study Section.
• 2023 Elected Vice-Chair of the Vascular Cognitive disorders Professional Interest Area of the Alzheimer’s Association.
• 2023 Selected Member of the Scientific Program Committee for the Alzheimer’s Association International Conference (AAIC) 2023-2027.
• 2023-Present Scientific Program Committee Member for the Alzheimer’s Association International Conference (AAIC) 2023-2027.
• 2024 Dawn Marks Faculty Award for Teaching, Mentoring and dedication to Graduate Student’s life and community.
• 2024 Co-Chair of the Vascular Contributions to Cognitive Impairment (VCID) Session of the 2025 NIH/NINDS ADRD Summit.
• 2025 Educational Excellence Award in Research Mentoring, Temple University LKSOM.
• 2025 Elected Chair of the Vascular Cognitive Disorders Professional Interest Area of the Alzheimer’s Association.
• 07/2024-06/2025 Interim Director Alzheimer’s Center at Temple (ACT), Associate Professor of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia.
• 2025 Director, Alzheimer’s Center at Temple (ACT), Professor (Tenured) of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia. Scott Richards North Star Foundation and Stop Alzheimer’s Now Chair in Alzheimer’s Research.
• 2025 Chair of the Vascular Cognitive disorders Professional Interest Area of the Alzheimer’s Association (ISTAART).
• 2026 Named the Scott Richards North Star Foundation and Stop Alzheimer’s Now Chair in Alzheimer’s Research.

PUBLICATIONS

NCBI Bibliography

1. Poor R-wave progression associates with cerebral amyloid deposition: A potential link between heart and brain. Sozio SJ, Sahai A, Khalafi M, Wang X, Tanzi E, Harvey P, Maloney T, Hojjati SH, Zhou L, Pahlajani S, Butler TA, Glodzik L, Li Y, Razlighi Q, Kim J, Goyal P, Fossati S, Chiang GC. J Alzheimers Dis. 2026 Jul;112(1):188-197. doi: 10.1177/13872877261449510. Epub 2026 Jun 4. PMID: 42244199
2. Mitochondrial carbonic anhydrase-VB inhibition rescues brain endothelial stress and memory in Alzheimer's disease models. Lemon NL, Canepa E, Vázquez-Torres R, Parodi-Rullán R, Hirt T, Petersohn LM, Rifat T, Abyaneh MH, Ilies MA, Fossati S. bioRxiv [Preprint]. 2026 Mar 18:2026.03.16.711716. doi: 10.64898/2026.03.16.711716. PMID: 41890077
3. Lack of Oxygen and/or Glucose Differentially Potentiates Aβ40e22q- and Aβ42-Induced Cerebral Endothelial Cell Death, Barrier Dysfunction and Angiogenesis Impairment. Carey A, Buzhdygan T, Fossati S. Cells. 2026 Feb 27;15(5):424. doi: 10.3390/cells15050424. PMID: 41827857
4. Amyloid β Instigates Cardiac Neurotrophic Signaling Impairment, Driving Alzheimer's Associated Heart Disease. Elia A, Parodi-Rullan R, Vazquez-Torres R, Carey A, Zhao H, Javadov S, Fossati S. Adv Sci (Weinh). 2026 Apr;13(20):e11924. doi: 10.1002/advs.202511924. Epub 2026 Feb 10. PMID: 41665021
5. Organelle stresses and energetic metabolisms promote endothelial-to-mesenchymal transition and fibrosis via upregulating FOSB and MEOX1 in Alzheimer's disease. Saaoud F, Ben Issa M, Liu L, Xu K, Lu Y, Shao Y, Han B, Jiang X, Liu X, Gillespie A, Luo JJ, Martinez L, Vazquez-Padron R, Mohsin S, Kosmider B, Wang H, Fossati S, Yang X. Front Mol Neurosci. 2025 Aug 22;18:1605012. doi: 10.3389/fnmol.2025.1605012. eCollection 2025.
6. IL-19 Is a Novel Lymphangiocrine Factor Inducing Lymphangiogenesis and Lymphatic Junctional Regulation. Peluzzo AM, St Paul A, Corbett CB, Kelemen SE, Fossati S, Liu X, Autieri MV. Arterioscler Thromb Vasc Biol. 2025 Jul;45(7):1244-1265. doi: 10.1161/ATVBAHA.125.322669. Epub 2025 May 15. PMID: 40371466
7. Cerebral proteome adaptations to amyloid angiopathy are prevented by carbonic anhydrase inhibitors. Carlsen J, Fossati S, Østergaard L, Gutiérrez-Jiménez E, Palmfeldt J. Alzheimers Dement. 2025 Apr;21(4):e70122. doi: 10.1002/alz.70122. PMID: 40285374
8. Carbonic anhydrase inhibitors prevent presymptomatic capillary flow disturbances in a model of cerebral amyloidosis. Gutiérrez-Jiménez E, Rasmussen PM, Mikkelsen IK, Kura S, Fruekilde SK, Hansen B, Bordoni L, Carlsen J, Palmfeldt J, Boas DA, Sakadžić S, Vinogradov S, Khatib ME, Ramos-Cejudo J, Wied B, Leduc-Galindo D, Canepa E, Mar AC, Gamallo-Lana B, Fossati S, Østergaard L. Alzheimers Dement. 2025 Mar;21(3):e70023. doi: 10.1002/alz.70023. PMID: 40133235
9. Fibrillar tau alters cerebral endothelial cell metabolism, vascular inflammatory activation, and barrier function in vitro and in vivo. Guzmán-Hernández R, Fossati S. Alzheimers Dement. 2025 Mar;21(3):e70077. doi: 10.1002/alz.70077. PMID: 40110691
10. Homocysteine potentiates amyloid β -induced death receptor 4- and 5-mediated cerebral endothelial cell apoptosis, blood brain barrier dysfunction and angiogenic impairment. Carey A, Parodi-Rullan R, Vazquez-Torres R, Canepa E, Fossati S. Aging Cell. 2024 May;23(5):e14106. doi: 10.1111/acel.14106. Epub 2024 Feb 15. PMID: 38358083
11. Amyloid Beta Oligomers Activate Death Receptors and Mitochondria-Mediated Apoptotic Pathways in Cerebral Vascular Smooth Muscle Cells; Protective Effects of Carbonic Anhydrase Inhibitors. Anzovino A, Canepa E, Alves M, Lemon NL, Carare RO, Fossati S. Cells. 2023 Dec 14;12(24):2840. doi: 10.3390/cells12242840. PMID: 38132159
12. Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA), updates in 2022-2023. Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy. Kelly L, Brown C, Michalik D, Hawkes CA, Aldea R, Agarwal N, Salib R, Alzetani A, Ethell DW, Counts SE, de Leon M, Fossati S, Koronyo-Hamaoui M, Piazza F, Rich SA, Wolters FJ, Snyder H, Ismail O, Elahi F, Proulx ST, Verma A, Wunderlich H, Haack M, Dodart JC, Mazer N, Carare RO. Alzheimers Dement. 2024 Feb;20(2):1421-1435. doi: 10.1002/alz.13512. Epub 2023 Oct 28. PMID: 37897797
13. Amyloid β instigates cardiac neurotrophic signaling impairment, driving Alzheimer's associated heart disease. Elia A, Parodi-Rullan R, Vazquez-Torres R, Carey A, Javadov S, Fossati S. bioRxiv [Preprint]. 2025 Jun 4:2023.07.11.548558. doi: 10.1101/2023.07.11.548558. Update in: Adv Sci (Weinh). 2026 Apr;13(20):e11924. doi: 10.1002/advs.202511924. PMID: 37502936
14. FDA-approved carbonic anhydrase inhibitors reduce amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness. Canepa E, Parodi-Rullan R, Vazquez-Torres R, Gamallo-Lana B, Guzman-Hernandez R, Lemon NL, Angiulli F, Debure L, Ilies MA, Østergaard L, Wisniewski T, Gutiérrez-Jiménez E, Mar AC, Fossati S. Alzheimers Dement. 2023 Nov;19(11):5048-5073. doi: 10.1002/alz.13063. Epub 2023 Apr 26. PMID: 37186121
15. The Effects of Amyloid-β on Metabolomic Profiles of Cardiomyocytes and Coronary Endothelial Cells. Jang S, Chorna N, Rodríguez-Graciani KM, Inyushin M, Fossati S, Javadov S. J Alzheimers Dis. 2023;93(1):307-319. doi: 10.3233/JAD-221199. PMID: 36970904
16. Screening for PTSD and TBI in Veterans using Routine Clinical Laboratory Blood Tests. Xu M, Lin Z, Siegel CE, Laska EM, Abu-Amara D, Genfi A, Newman J, Jeffers MK, Blessing EM, Flanagan SR, Fossati S, Etkin A, Marmar CR. Transl Psychiatry. 2023 Feb 21;13(1):64. doi: 10.1038/s41398-022-02298-x. PMID: 36810280
17. Autonomic nervous system and cardiac neuro-signaling pathway modulation in cardiovascular disorders and Alzheimer's disease. Elia A, Fossati S. Front Physiol. 2023 Jan 30;14:1060666. doi: 10.3389/fphys.2023.1060666. eCollection 2023. PMID: 36798942
18. Editorial: Women in aging neuroscience 2021. Fossati S. Front Aging Neurosci. 2023 Jan 26;15:1140899. doi: 10.3389/fnagi.2023.1140899. eCollection 2023. PMID: 36776435
19. Hypertension and hyperhomocysteinemia as modifiable risk factors for Alzheimer's disease and dementia: New evidence, potential therapeutic strategies, and biomarkers. Carey A, Fossati S. Alzheimers Dement. 2023 Feb;19(2):671-695. doi: 10.1002/alz.12871. Epub 2022 Nov 19. PMID: 36401868
20. CRF serum levels differentiate PTSD from healthy controls and TBI in military veterans. Ramos-Cejudo J, Genfi A, Abu-Amara D, Debure L, Qian M, Laska E, Siegel C, Milton N, Newman J, Blessing E, Li M, Etkin A, Marmar CR, Fossati S. Psychiatr Res Clin Pract. 2021 Winter;3(4):153-162. doi: 10.1176/appi.prcp.20210017. Epub 2021 Jun 1. PMID: 35211666
21. Beta-Amyloid Instigates Dysfunction of Mitochondria in Cardiac Cells. Jang S, Chapa-Dubocq XR, Parodi-Rullán RM, Fossati S, Javadov S. Cells. 2022 Jan 22;11(3):373. doi: 10.3390/cells11030373. PMID: 35159183
22. Analysis of Mitochondrial Calcium Retention Capacity in Cultured Cells: Permeabilized Cells Versus Isolated Mitochondria. Jang S, Chapa-Dubocq XR, Fossati S, Javadov S. Front Physiol. 2021 Dec 7;12:773839. doi: 10.3389/fphys.2021.773839. eCollection 2021. PMID: 34950052
23. Carbonic Anhydrases as Potential Targets Against Neurovascular Unit Dysfunction in Alzheimer's Disease and Stroke. Lemon N, Canepa E, Ilies MA, Fossati S. Front Aging Neurosci. 2021 Nov 16;13:772278. doi: 10.3389/fnagi.2021.772278. eCollection 2021. PMID: 34867298
24. Dissecting the Crosstalk between Endothelial Mitochondrial Damage, Vascular Inflammation, and Neurodegeneration in Cerebral Amyloid Angiopathy and Alzheimer's Disease. Parodi-Rullán RM, Javadov S, Fossati S. Cells. 2021 Oct 27;10(11):2903. doi: 10.3390/cells10112903. PMID: 34831125
25. Reader Response: Blood Biomarkers of Traumatic Brain Injury and Cognitive Impairment in Older Veterans. Wisniewski T, Fossati S. Neurology. 2021 Jul 13;97(2):101. doi: 10.1212/WNL.0000000000012255. PMID: 34253655
26. Impact of Tau on Neurovascular Pathology in Alzheimer's Disease. Canepa E, Fossati S. Front Neurol. 2021 Jan 7;11:573324. doi: 10.3389/fneur.2020.573324. eCollection 2020. PMID: 33488493
27. Alzheimer's amyloid β heterogeneous species differentially affect brain endothelial cell viability, blood-brain barrier integrity, and angiogenesis. Parodi-Rullán R, Ghiso J, Cabrera E, Rostagno A, Fossati S. Aging Cell. 2020 Nov;19(11):e13258. doi: 10.1111/acel.13258. Epub 2020 Nov 6. PMID: 33155752
28. Plasma tau predicts cerebral vulnerability in aging. Cantero JL, Atienza M, Ramos-Cejudo J, Fossati S, Wisniewski T, Osorio RS. Aging (Albany NY). 2020 Nov 4;12(21):21004-21022. doi: 10.18632/aging.104057. Epub 2020 Nov 4. PMID: 33147571
29. Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA): Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's disease-Opportunities for Therapy. Carare RO, Aldea R, Agarwal N, Bacskai BJ, Bechman I, Boche D, Bu G, Bulters D, Clemens A, Counts SE, de Leon M, Eide PK, Fossati S, Greenberg SM, Hamel E, Hawkes CA, Koronyo-Hamaoui M, Hainsworth AH, Holtzman D, Ihara M, Jefferson A, Kalaria RN, Kipps CM, Kanninen KM, Leinonen V, McLaurin J, Miners S, Malm T, Nicoll JAR, Piazza F, Paul G, Rich SM, Saito S, Shih A, Scholtzova H, Snyder H, Snyder P, Thormodsson FR, van Veluw SJ, Weller RO, Werring DJ, Wilcock D, Wilson MR, Zlokovic BV, Verma A. Alzheimers Dement (Amst). 2020 Aug 3;12(1):e12053. doi: 10.1002/dad2.12053. eCollection 2020. PMID: 32775596
30. Editorial: Identification of Multiple Targets in the Fight Against Alzheimer's Disease. Giannoni P, Fossati S, Marcello E, Claeysen S. Front Aging Neurosci. 2020 Jun 16;12:169. doi: 10.3389/fnagi.2020.00169. eCollection 2020. PMID: 32612524
31. Effect of Combat Exposure and Posttraumatic Stress Disorder on Telomere Length and Amygdala Volume. Kang JI, Mueller SG, Wu GWY, Lin J, Ng P, Yehuda R, Flory JD, Abu-Amara D, Reus VI, Gautam A; PTSD Systems Biology Consortium; Hammamieh R, Doyle FJ 3rd, Jett M, Marmar CR, Mellon SH, Wolkowitz OM. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Jul;5(7):678-687. doi: 10.1016/j.bpsc.2020.03.007. Epub 2020 Mar 31. PMID: 32439402
32. A New Kid on the Block? Carbonic Anhydrases as Possible New Targets in Alzheimer's Disease. Provensi G, Carta F, Nocentini A, Supuran CT, Casamenti F, Passani MB, Fossati S. Int J Mol Sci. 2019 Sep 24;20(19):4724. doi: 10.3390/ijms20194724. PMID: 31554165
33. Multi-omic biomarker identification and validation for diagnosing warzone-related post-traumatic stress disorder. Dean KR, Hammamieh R, Mellon SH, Abu-Amara D, Flory JD, Guffanti G, Wang K, Daigle BJ Jr, Gautam A, Lee I, Yang R, Almli LM, Bersani FS, Chakraborty N, Donohue D, Kerley K, Kim TK, Laska E, Young Lee M, Lindqvist D, Lori A, Lu L, Misganaw B, Muhie S, Newman J, Price ND, Qin S, Reus VI, Siegel C, Somvanshi PR, Thakur GS, Zhou Y; PTSD Systems Biology Consortium; Hood L, Ressler KJ, Wolkowitz OM, Yehuda R, Jett M, Doyle FJ 3rd, Marmar C. Mol Psychiatry. 2020 Dec;25(12):3337-3349. doi: 10.1038/s41380-019-0496-z. Epub 2019 Sep 10. PMID: 31501510
34. Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease. Fossati S, Ramos Cejudo J, Debure L, Pirraglia E, Sone JY, Li Y, Chen J, Butler T, Zetterberg H, Blennow K, de Leon MJ. Alzheimers Dement (Amst). 2019 Jun 28;11:483-492. doi: 10.1016/j.dadm.2019.05.001. eCollection 2019 Dec. PMID: 31334328
35. Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimer's Disease. Parodi-Rullán R, Sone JY, Fossati S. J Alzheimers Dis. 2019;72(4):1019-1039. doi: 10.3233/JAD-190357. PMID: 31306129
36. White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities. Alber J, Alladi S, Bae HJ, Barton DA, Beckett LA, Bell JM, Berman SE, Biessels GJ, Black SE, Bos I, Bowman GL, Brai E, Brickman AM, Callahan BL, Corriveau RA, Fossati S, Gottesman RF, Gustafson DR, Hachinski V, Hayden KM, Helman AM, Hughes TM, Isaacs JD, Jefferson AL, Johnson SC, Kapasi A, Kern S, Kwon JC, Kukolja J, Lee A, Lockhart SN, Murray A, Osborn KE, Power MC, Price BR, Rhodius-Meester HFM, Rondeau JA, Rosen AC, Rosene DL, Schneider JA, Scholtzova H, Shaaban CE, Silva NCBS, Snyder HM, Swardfager W, Troen AM, van Veluw SJ, Vemuri P, Wallin A, Wellington C, Wilcock DM, Xie SX, Hainsworth AH. Alzheimers Dement (N Y). 2019 Apr 9;5:107-117. doi: 10.1016/j.trci.2019.02.001. eCollection 2019. PMID: 31011621
37. Using fMRI connectivity to define a treatment-resistant form of post-traumatic stress disorder. Etkin A, Maron-Katz A, Wu W, Fonzo GA, Huemer J, Vértes PE, Patenaude B, Richiardi J, Goodkind MS, Keller CJ, Ramos-Cejudo J, Zaiko YV, Peng KK, Shpigel E, Longwell P, Toll RT, Thompson A, Zack S, Gonzalez B, Edelstein R, Chen J, Akingbade I, Weiss E, Hart R, Mann S, Durkin K, Baete SH, Boada FE, Genfi A, Autea J, Newman J, Oathes DJ, Lindley SE, Abu-Amara D, Arnow BA, Crossley N, Hallmayer J, Fossati S, Rothbaum BO, Marmar CR, Bullmore ET, O'Hara R. Sci Transl Med. 2019 Apr 3;11(486):eaal3236. doi: 10.1126/scitranslmed.aal3236. PMID: 30944165
38. Carbonic anhydrase inhibition selectively prevents amyloid β neurovascular mitochondrial toxicity. Solesio ME, Peixoto PM, Debure L, Madamba SM, de Leon MJ, Wisniewski T, Pavlov EV, Fossati S. Aging Cell. 2018 Aug;17(4):e12787. doi: 10.1111/acel.12787. Epub 2018 Jun 5. PMID: 29873184
39. The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease. de Leon MJ, Pirraglia E, Osorio RS, Glodzik L, Saint-Louis L, Kim HJ, Fortea J, Fossati S, Laska E, Siegel C, Butler T, Li Y, Rusinek H, Zetterberg H, Blennow K; Alzheimer’s Disease Neuroimaging Initiative; National Alzheimer’s Coordinating Center. PLoS One. 2018 Feb 7;13(2):e0191240. doi: 10.1371/journal.pone.0191240. eCollection 2018. PMID: 29415068
40. Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link Ramos-Cejudo J, Wisniewski T, Marmar C, Zetterberg H, Blennow K, de Leon MJ, Fossati S. EBioMedicine. 2018 Feb;28:21-30. doi: 10.1016/j.ebiom.2018.01.021. Epub 2018 Jan 31. PMID: 29396300
41. Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET. de Leon MJ, Li Y, Okamura N, Tsui WH, Saint-Louis LA, Glodzik L, Osorio RS, Fortea J, Butler T, Pirraglia E, Fossati S, Kim HJ, Carare RO, Nedergaard M, Benveniste H, Rusinek H. J Nucl Med. 2017 Sep;58(9):1471-1476. doi: 10.2967/jnumed.116.187211. Epub 2017 Mar 16. PMID: 28302766
42. The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. Fossati S, Giannoni P, Solesio ME, Cocklin SL, Cabrera E, Ghiso J, Rostagno A. Neurobiol Dis. 2016 Feb;86:29-40. doi: 10.1016/j.nbd.2015.11.006. Epub 2015 Nov 12. PMID: 26581638
43. Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease. Spiegel J, Pirraglia E, Osorio RS, Glodzik L, Li Y, Tsui W, Saint Louis LA, Randall C, Butler T, Xu J, Zinkowski RP, Zetterberg H, Fortea J, Fossati S, Wisniewski T, Davies P, Blennow K, de Leon MJ. J Alzheimers Dis. 2016;49(1):93-100. doi: 10.3233/JAD-150167. PMID: 26444757
44. Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration. Todd K, Fossati S, Ghiso J, Rostagno A. Biochim Biophys Acta. 2014 Dec;1842(12 Pt A):2457-67. doi: 10.1016/j.bbadis.2014.09.010. Epub 2014 Sep 28. PMID: 25261792
45. Amyloidosis associated with cerebral amyloid angiopathy: cell signaling pathways elicited in cerebral endothelial cells. Ghiso J, Fossati S, Rostagno A. J Alzheimers Dis. 2014;42 Suppl 3(0 3):S167-76. doi: 10.3233/JAD-140027. PMID: 24670400
46. Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid β and the Asn23 Iowa mutation. Fossati S, Todd K, Sotolongo K, Ghiso J, Rostagno A. Biochem J. 2013 Dec 15;456(3):347-60. doi: 10.1042/BJ20130652. PMID: 24028142
47. Insights into caspase-mediated apoptotic pathways induced by amyloid-β in cerebral microvascular endothelial cells. Fossati S, Ghiso J, Rostagno A. Neurodegener Dis. 2012;10(1-4):324-8. doi: 10.1159/000332821. Epub 2011 Dec 7. PMID: 22156599
48. Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-beta E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells. Hernandez-Guillamon M, Mawhirt S, Fossati S, Blais S, Pares M, Penalba A, Boada M, Couraud PO, Neubert TA, Montaner J, Ghiso J, Rostagno A. J Biol Chem. 2010 Aug 27;285(35):27144-27158. doi: 10.1074/jbc.M110.135228. Epub 2010 Jun 24. PMID: 20576603
49. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Faraco G, Pittelli M, Cavone L, Fossati S, Porcu M, Mascagni P, Fossati G, Moroni F, Chiarugi A. Neurobiol Dis. 2009 Nov;36(2):269-79. doi: 10.1016/j.nbd.2009.07.019. Epub 2009 Jul 25. PMID: 19635561
50. Dutch and Arctic mutant peptides of beta amyloid(1-40) differentially affect the FGF-2 pathway in brain endothelium. Solito R, Corti F, Fossati S, Mezhericher E, Donnini S, Ghiso J, Giachetti A, Rostagno A, Ziche M. Exp Cell Res. 2009 Feb 1;315(3):385-95. doi: 10.1016/j.yexcr.2008.11.002. Epub 2008 Nov 19. PMID: 19061884
51. Relevance of high-mobility group protein box 1 to neurodegeneration. Fossati S, Chiarugi A. Int Rev Neurobiol. 2007;82:137-48. doi: 10.1016/S0074-7742(07)82007-1. PMID: 17678959
52. A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. Aldinucci A, Gerlini G, Fossati S, Cipriani G, Ballerini C, Biagioli T, Pimpinelli N, Borgognoni L, Massacesi L, Moroni F, Chiarugi A. J Immunol. 2007 Jul 1;179(1):305-12. doi: 10.4049/jimmunol.179.1.305. PMID: 1757905
53. Carboxymethyl beta-glucan binds to corneal epithelial cells and increases cell adhesion to laminin and resistance to oxidative stress. Porcu M, Guarna F, Formentini L, Faraco G, Fossati S, Mencucci R, Rapizzi E, Menchini U, Moroni F, Chiarugi A. Cornea. 2007 Jan;26(1):73-9. doi: 10.1097/ICO.0b013e31802e3872. PMID: 17198017
54. Poly(ADP-ribosyl)ation regulates heat shock factor-1 activity and the heat shock response in murine fibroblasts. Fossati S, Formentini L, Wang ZQ, Moroni F, Chiarugi A. Biochem Cell Biol. 2006 Oct;84(5):703-12. doi: 10.1139/o06-083. PMID: 17167533
55. Neither energy collapse nor transcription underlie in vitro neurotoxicity of poly(ADP-ribose) polymerase hyper-activation. Fossati S, Cipriani G, Moroni F, Chiarugi A. Neurochem Int. 2007 Jan;50(1):203-10. doi: 10.1016/j.neuint.2006.08.009. Epub 2006 Oct 18. PMID: 17052800
56. Poly(ADP-ribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice. Cozzi A, Cipriani G, Fossati S, Faraco G, Formentini L, Min W, Cortes U, Wang ZQ, Moroni F, Chiarugi A. J Cereb Blood Flow Metab. 2006 May;26(5):684-95. doi: 10.1038/sj.jcbfm.9600222. PMID: 16177811
57. Inhibition of poly(ADP-ribose) glycohydrolase by gallotannin selectively up-regulates expression of proinflammatory genes. Rapizzi E, Fossati S, Moroni F, Chiarugi A. Mol Pharmacol. 2004 Oct;66(4):890-8. doi: 10.1124/mol.104.000968. Epub 2004 Jun 30. PMID: 15229295